Companies › Rhizen Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tenalisib (RP6530) PI3-kinase p110-delta subunit inhibitor; PI3-kinase p110-gamma subunit inhibitor | PIK3CD, PIK3CG | Phase 2 | Triple Negative Breast Cancer (TNBC) | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06189209 | Tenalisib (RP6530) | Phase 2 | Triple Negative Breast Cancer (TNBC) | Oncology | Dec 2026 |
SecuraBio Incyte Biosciences Japan GK Pharming Technologies Incyte Kyowa Kirin Restorbio Celcuity Eli Lilly Sovargen Stelexis BioSciences
SecuraBio Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.